Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NATALIZUMAB-SZTN: 188 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
188
Total FAERS Reports
2 (1.1%)
Deaths Reported
18
Hospitalizations
188
As Primary/Secondary Suspect
5
Life-Threatening
40
Disabilities
Prescription
Status

FDA Application: 761322 ·

First Report: 20231216 · Latest Report: 20250730

What Are the Most Common NATALIZUMAB-SZTN Side Effects?

#1 Most Reported
Fatigue
63 reports (33.5%)
#2 Most Reported
Mobility decreased
52 reports (27.7%)
#3 Most Reported
Balance disorder
31 reports (16.5%)

All NATALIZUMAB-SZTN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Fatigue 63 33.5% 0 3
Mobility decreased 52 27.7% 0 0
Balance disorder 31 16.5% 0 2
Headache 18 9.6% 0 3
Product substitution issue 17 9.0% 2 3
Multiple sclerosis relapse 16 8.5% 0 1
Muscular weakness 16 8.5% 0 0
Cognitive disorder 13 6.9% 0 0
Gait disturbance 13 6.9% 0 0
Dizziness 11 5.9% 0 1
Nausea 9 4.8% 0 0
Urinary incontinence 9 4.8% 0 0
Arthralgia 7 3.7% 0 2
Dysphagia 7 3.7% 0 0
Musculoskeletal stiffness 7 3.7% 0 2
Paraesthesia 7 3.7% 0 0
Progressive multifocal leukoencephalopathy 7 3.7% 2 5
Rash 7 3.7% 0 1
Abdominal distension 6 3.2% 0 0
Alopecia 6 3.2% 0 0

Who Reports NATALIZUMAB-SZTN Side Effects? Age & Gender Data

Gender: 84.7% female, 15.3% male. Average age: 47.0 years. Most reports from: GB. View detailed demographics →

Is NATALIZUMAB-SZTN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2023 1 0 1
2024 140 0 8
2025 10 0 2

View full timeline →

What Is NATALIZUMAB-SZTN Used For?

IndicationReports
Multiple sclerosis 142
Product used for unknown indication 33
Relapsing-remitting multiple sclerosis 10

NATALIZUMAB-SZTN vs Alternatives: Which Is Safer?

NATALIZUMAB-SZTN vs NATAMYCIN NATALIZUMAB-SZTN vs NATEGLINIDE NATALIZUMAB-SZTN vs NAVITOCLAX NATALIZUMAB-SZTN vs NAXITAMAB-GQGK NATALIZUMAB-SZTN vs NEBIVOLOL NATALIZUMAB-SZTN vs NECITUMUMAB NATALIZUMAB-SZTN vs NEDAPLATIN NATALIZUMAB-SZTN vs NEFAZODONE NATALIZUMAB-SZTN vs NEFOPAM NATALIZUMAB-SZTN vs NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN\NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE\NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIG

Official FDA Label for NATALIZUMAB-SZTN

Official prescribing information from the FDA-approved drug label.